Conspicuously, our data further suggest an association of RAD51 expression in CTCs towards the end of treatment with worse survival, which is in accordance with literature data revealing high RAD51 mRNA expression in BC, particularly in TNBC and advanced stages with poor prognosis.50 The gene discussed is RAD51; the disease is breast cancer.